[iHub News]

BeyondSpring shares rise after narrower quarterly loss and pipeline advances (BYSI)

May 13, 2026 9:29 AM
IH Market News

Shares of BeyondSpring (NASDAQ:BYSI) climbed more than 6% in premarket trading on Wednesday after the company reported a smaller loss from continuing operations and highlighted progress across its development pipeline.

The stock gained 6.47% following the earnings update.

Quarterly loss narrows year-on-year

BeyondSpring reported a net loss from continuing operations of $2.4 million for the three months ended March 31, 2026, compared with a loss of $2.6 million during the same quarter last year.

The company did not record any revenue during the quarter.

As of March 31, 2026, BeyondSpring held $7.9 million in cash, cash equivalents and short-term investments.

Research spending increases as development progresses

Research and development expenses rose to $1.1 million from $0.9 million a year earlier.

The company said the increase was driven by expanded drug manufacturing activities in preparation for potential future clinical studies.

General and administrative expenses declined to $1.1 million from $1.7 million in the prior-year period, mainly due to lower personnel-related and legal advisory costs.

Company highlights AACR 2026 data for Plinabulin

BeyondSpring pointed to new data presented at the AACR Annual Meeting 2026 showing that Plinabulin significantly improved both efficacy and tolerability in antibody-drug conjugate regimens based on topoisomerase inhibitors.

According to the company, preclinical findings demonstrated stronger complete response rates, improved survival outcomes and enhanced immune responses.

“Plinabulin continues to demonstrate the ability to enhance both efficacy and tolerability in ADC-based regimens, supporting its positioning as a potential backbone agent across a rapidly evolving treatment landscape,” said Lan Huang, co-founder, chair and chief executive officer of BeyondSpring.

SEED Therapeutics advances Phase 1 programme

At SEED Therapeutics, BeyondSpring advanced ST-01156, described as a novel RBM39 molecular glue degrader, into Phase 1 clinical development.

The company said the first dosing cohort has already been completed.

Additional data presented at AACR 2026 showed complete tumour eradication in an in vivo neuroblastoma model.

Discontinued operations weigh on overall results

BeyondSpring recorded a net loss from discontinued operations of $4.3 million during the quarter.

In the same period last year, the company reported net income from discontinued operations of $3.8 million.

BeyondSpring stock price

Original: BeyondSpring shares rise after narrower quarterly loss and pipeline advances (BYSI)

[glenn1919]

BYSI...................................................p/m

[tw0122]

Nice pump done now out of it

[glenn1919]

BYSI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,https://stockcharts.com/sc3/ui/?s=BYSI&p=W&b=5&g=0&id=p86431144783

[Monksdream]

BYSI 10Q expected Monday 6/24

[glenn1919]

BYSI.................................https://stockcharts.com/h-sc/ui?s=BYSI&p=W&b=5&g=0&id=p86431144783

[Monksdream]

BYSI under $5

[glenn1919]

BYSI..........................................https://stockcharts.com/h-sc/ui?s=BYSI&p=W&b=5&g=0&id=p86431144783

[Monksdream]

BYSI new 52 week high

[Monksdream]

BYSI new 52 week high

[glenn1919]

BYSI................................https://stockcharts.com/h-sc/ui?s=BYSI&p=D&yr=0&mn=2&dy=12&id=p84071410134

[Monksdream]

BYSI under $2

[TheFinalCD]

https://finviz.com/quote.ashx?t=BYSI&p=d

[makinezmoney]

$BYSI: And shes back now................ $1.10

BOOOOOOOOOommmmmmmmmmmmmmmm


HELLO.............. nice to be on the win side here again



GO $BYSI

[Montanore]

Nice green pop here today on a down day for the market.

[CarlCarlMcB]

News is Great!!!!!$$$$$$$$$$ 25.00 to 48.00

[CarlCarlMcB]

Your not kidding $

[CarlCarlMcB]

Wow I say Merry Christmas $$$$$$
45.00 65.00 let’s go!!!!

[JackAskSlap]

That'd be right up my alley treat them all like 000..

[CarlCarlMcB]

You think ? .000001

[Montanore]

Egad, what a disaster.

But maybe worth picking up some bargain shares here...

[Longer Than Most]

BYSI lotto sub 6

[JackAskSlap]

Overreactions easiest money on the planet

[TheFinalCD]

$6^ bouncing some

[saigai]

damn sesn all over again. but i dodged this one got sluaghtered on sesn

[TheFinalCD]

$5 *FAIL* https://ih.advfn.com/stock-market/NASDAQ/beyondspring-BYSI/stock-news/86697907/beyondspring-fails-to-win-fda-approval-for-plinabu

[TheFinalCD]

https://ih.advfn.com/stock-market/NASDAQ/beyondspring-BYSI/stock-news/86697835/report-of-foreign-issuer-pursuant-to-rule-13a-16-o

[TheFinalCD]

In September, BeyondSpring tanked after the company gave investors a closer look at Dublin-3 data. In a nutshell, the treatment might not be any more effective than existing options.

Recent lung cancer data was a little disappointing, but investors may be missing the point here. Plinabulin isn't intended to fight cancer directly. It's meant to stop toxic chemotherapy from destroying white blood cells. A lack of white blood cells, or neutropenia, is a dangerous complication that frequently interrupts chemotherapy treatment.

On or before Nov. 30, 2021, the FDA is expected to issue an approval decision for BeyondSpring's lead candidate plinabulin. If given a green light to treat chemotherapy-induced neutropenia, it could become an important new treatment for lots of different cancer patients.

Message in reply to:

BeyondSpring To Present Final Phase 3 DUBLIN-3 Data With Plinabulin/Docetaxel Combination Versus Docetaxel Alone In 2nd/3rd Line Non-Small Cell Lung Cancer Patients With EGFR Wild Type At European Society for Medical Oncology 2021 Congress Sept. 16-21

[TheFinalCD]

BYSI 13.50 HALTED UP ^^ PENDING NEWS))))))))))

[alvaroc2]

I Was in at 26$, what price target do you have crudeoil? Thanks in advance

[cjstocksup]

We had a great day today new highs $33.00.
BYSI

[crudeoil24]

33.00 > 52 wk. high!

[crudeoil24]

BeyondSpring To Present Final Phase 3 DUBLIN-3 Data With Plinabulin/Docetaxel Combination Versus Docetaxel Alone In 2nd/3rd Line Non-Small Cell Lung Cancer Patients With EGFR Wild Type At European Society for Medical Oncology 2021 Congress Sept. 16-21

[cjstocksup]

I know I love it.

[makinezmoney]

$BYSI: Now nicely over $31


This thing is gonna go muchhhhhhhhhhhhhhh higher



That NEWS relase 3wks ago was SUPER SOLID



GO BYSI

[crudeoil24]

The agreement with Jiangsu Hengrui is in the Greater China area for BeyondSpring's investigational drug candidate plinabulin. Plinabulin in combination with G-CSF is currently under review by the U.S. Food and Drug Administration and the China National Medical Products Administration to prevent chemotherapy-induced neutropenia. The territory for the agreement includes mainland China, Hong Kong, Macau and Taiwan.

[crudeoil24]

Exactly, on our way to $100.

$BYSI: Monster news....... Monster UPGRADE to $100 by Wainwright

No wonder its on a roll right now


This could be the next $SAVA big time mover



GO $BYSI

[crudeoil24]

BYSI moving on a co-development and commercialization agreement for chemotherapy-induced neutropenia treatment candidate.
BeyondSpring shares are trading higher after the company announced an exclusive commercialization and co-development agreement with Jiangsu Hengrui for Plinabulin in Greater China.

[cjstocksup]

Told everyone to be patient. We hit new 52 week highs today.
BYSI

[BoilerRoom]

No Sir

[Actualfactual]

Wow. Hope you held

[saigai]

for many people the news helps to lessen the fear of any need for an offerring beyond june 22...more money flow..we'll see

[Montanore]

Bought some of this dip today--hard not to.

[Actualfactual]

By the way the market looks it’s not beasting today

[BoilerRoom]

$BYSI I jumped back in today at $20.20. Have to swing trade this can’t sell tomorrow hope doesn’t pop today

[Actualfactual]

I dunno about it breaking $20..

[BoilerRoom]

Load up BYSI going to the moon!

[BoilerRoom]

Averaging down Jesus!

[BoilerRoom]

$BYSI back in for a quick flip

[BoilerRoom]

Wonder if this will ever bottom out? You would think cancer treatments would run. I would jump back in but volume has dried up folks lost interest. Government should ban medical stocks from being shorted. Sad companies try help sick people and some A-hole comes along trying push company’s price down.